267 related articles for article (PubMed ID: 23108159)
1. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.
Mitsuhashi H; Mitsuhashi S; Lynn-Jones T; Kawahara G; Kunkel LM
Hum Mol Genet; 2013 Feb; 22(3):568-77. PubMed ID: 23108159
[TBL] [Abstract][Full Text] [Related]
2. Transgenic zebrafish model of DUX4 misexpression reveals a developmental role in FSHD pathogenesis.
Pakula A; Lek A; Widrick J; Mitsuhashi H; Bugda Gwilt KM; Gupta VA; Rahimov F; Criscione J; Zhang Y; Gibbs D; Murphy Q; Manglik A; Mead L; Kunkel L
Hum Mol Genet; 2019 Jan; 28(2):320-331. PubMed ID: 30307508
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
4. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
5. Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD).
Jones TI; Parilla M; Jones PL
PLoS One; 2016; 11(3):e0150938. PubMed ID: 26942723
[TBL] [Abstract][Full Text] [Related]
6. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene.
Snider L; Geng LN; Lemmers RJ; Kyba M; Ware CB; Nelson AM; Tawil R; Filippova GN; van der Maarel SM; Tapscott SJ; Miller DG
PLoS Genet; 2010 Oct; 6(10):e1001181. PubMed ID: 21060811
[TBL] [Abstract][Full Text] [Related]
7. Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene.
Himeda CL; Debarnot C; Homma S; Beermann ML; Miller JB; Jones PL; Jones TI
Mol Cell Biol; 2014 Jun; 34(11):1942-55. PubMed ID: 24636994
[TBL] [Abstract][Full Text] [Related]
8. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
[TBL] [Abstract][Full Text] [Related]
9. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
10. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.
Wallace LM; Garwick SE; Mei W; Belayew A; Coppee F; Ladner KJ; Guttridge D; Yang J; Harper SQ
Ann Neurol; 2011 Mar; 69(3):540-52. PubMed ID: 21446026
[TBL] [Abstract][Full Text] [Related]
11. Direct interplay between two candidate genes in FSHD muscular dystrophy.
Ferri G; Huichalaf CH; Caccia R; Gabellini D
Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
[TBL] [Abstract][Full Text] [Related]
12. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
13. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
Banerji CRS; Zammit PS
EMBO Mol Med; 2021 Aug; 13(8):e13695. PubMed ID: 34151531
[TBL] [Abstract][Full Text] [Related]
14. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
[TBL] [Abstract][Full Text] [Related]
15. A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy.
Jones T; Jones PL
PLoS One; 2018; 13(2):e0192657. PubMed ID: 29415061
[TBL] [Abstract][Full Text] [Related]
16. Facioscapulohumeral Muscular Dystrophy.
DeSimone AM; Pakula A; Lek A; Emerson CP
Compr Physiol; 2017 Sep; 7(4):1229-1279. PubMed ID: 28915324
[TBL] [Abstract][Full Text] [Related]
17. Testing the effects of FSHD candidate gene expression in vertebrate muscle development.
Wuebbles RD; Long SW; Hanel ML; Jones PL
Int J Clin Exp Pathol; 2010 Mar; 3(4):386-400. PubMed ID: 20490329
[TBL] [Abstract][Full Text] [Related]
18. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
19. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
20. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
